Madelé van Dyk1, Jean-Claude Marshall2, Michael J Sorich1, Linda S Wood2, Andrew Rowland3. 1. College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide, SA, 5042, Australia. 2. Pfizer Worldwide Research and Development, Precision Medicine, Groton, CT, USA. 3. College of Medicine and Public Health, Flinders University, Bedford Park, Adelaide, SA, 5042, Australia. andrew.rowland@flinders.edu.au.
Abstract
PURPOSE: Cytochrome P450 (CYP) 3A4 is responsible for the metabolism of more than 30% of clinically used drugs. Inherent between subject variability in clearance of CYP3A4 substrates is substantial; by way of example, midazolam clearance varies by > 10-fold between individuals before considering the impact of extrinsic factors. Relatively little is known about inter-racial variability in the activity of this enzyme. METHODS: This study assessed inter-racial variability in midazolam exposure in a cohort (n = 30) of CYP3A genotyped, age-matched healthy males of Caucasian and South Asian ancestries. Midazolam exposure was assessed at baseline, following 7 days of rifampicin and following 3 days of clarithromycin. RESULTS: The geometric mean baseline midazolam area under the plasma concentration curve (AUC0-6) in Caucasians (1057 μg/L/min) was 27% greater than South Asians (768 μg/L/min). Similarly, the post-induction midazolam AUC0-6 in Caucasians (308 μg/L/min) was 50% greater than South Asians (154 μg/L/min), while the post-inhibition midazolam AUC0-6 in Caucasians (1834 μg/L/min) was 41% greater than South Asians (1079 μg/L/min). The difference in baseline AUC0-6 between Caucasians and South Asians was statistically significant (p ≤ 0.05), and a trend toward significance (p = 0.067) was observed for the post-induction AUC0-6 ratio, in both unadjusted and genotype adjusted analyses. CONCLUSIONS: Significantly higher midazolam clearance was observed in healthy age-matched males of South Asian compared to Caucasian ancestry that was not explained by differences in the frequency of CYP3A genotypes.
PURPOSE: Cytochrome P450 (CYP) 3A4 is responsible for the metabolism of more than 30% of clinically used drugs. Inherent between subject variability in clearance of CYP3A4 substrates is substantial; by way of example, midazolam clearance varies by > 10-fold between individuals before considering the impact of extrinsic factors. Relatively little is known about inter-racial variability in the activity of this enzyme. METHODS: This study assessed inter-racial variability in midazolam exposure in a cohort (n = 30) of CYP3A genotyped, age-matched healthy males of Caucasian and South Asian ancestries. Midazolam exposure was assessed at baseline, following 7 days of rifampicin and following 3 days of clarithromycin. RESULTS: The geometric mean baseline midazolam area under the plasma concentration curve (AUC0-6) in Caucasians (1057 μg/L/min) was 27% greater than South Asians (768 μg/L/min). Similarly, the post-induction midazolam AUC0-6 in Caucasians (308 μg/L/min) was 50% greater than South Asians (154 μg/L/min), while the post-inhibition midazolam AUC0-6 in Caucasians (1834 μg/L/min) was 41% greater than South Asians (1079 μg/L/min). The difference in baseline AUC0-6 between Caucasians and South Asians was statistically significant (p ≤ 0.05), and a trend toward significance (p = 0.067) was observed for the post-induction AUC0-6 ratio, in both unadjusted and genotype adjusted analyses. CONCLUSIONS: Significantly higher midazolam clearance was observed in healthy age-matched males of South Asian compared to Caucasian ancestry that was not explained by differences in the frequency of CYP3A genotypes.
Entities:
Keywords:
Caucasian; Cytochrome P450 3A4; Inducibility; Inter-racial variability; Pharmacokinetics; South Asian
Authors: Andrew Rowland; Madelé van Dyk; Arduino A Mangoni; John O Miners; Ross A McKinnon; Michael D Wiese; Angela Rowland; Ganessan Kichenadasse; Howard Gurney; Michael J Sorich Journal: Expert Opin Drug Metab Toxicol Date: 2016-09-01 Impact factor: 4.481
Authors: Rajaa A Mirghani; Jane Sayi; Eleni Aklillu; Annika Allqvist; Mary Jande; Agneta Wennerholm; Jaran Eriksen; Virginie M M Herben; Barry C Jones; Lars L Gustafsson; Leif Bertilsson Journal: Pharmacogenet Genomics Date: 2006-09 Impact factor: 2.089
Authors: Hong-Guang Xie; Alastair J J Wood; Richard B Kim; C Michael Stein; Grant R Wilkinson Journal: Pharmacogenomics Date: 2004-04 Impact factor: 2.533
Authors: Hobart Owen Ng Tsai; Janice Jia Ni Goh; Jernice Wan Xin Aw; Yingying Lin; Alan Yean Yip Fong; Lee Len Tiong; Doreen Su-Yin Tan Journal: J Thromb Thrombolysis Date: 2018-11 Impact factor: 2.300
Authors: Andrew Rowland; Warit Ruanglertboon; Madelé van Dyk; Dhilushi Wijayakumara; Linda S Wood; Robyn Meech; Peter I Mackenzie; A David Rodrigues; Jean-Claude Marshall; Michael J Sorich Journal: Br J Clin Pharmacol Date: 2018-11-16 Impact factor: 4.335
Authors: Ashley M Hopkins; Bradley D Menz; Michael D Wiese; Ganessan Kichenadasse; Howard Gurney; Ross A McKinnon; Andrew Rowland; Michael J Sorich Journal: Pharmacol Res Perspect Date: 2020-08
Authors: Madelé van Dyk; Asha J Kapetas; Ashley M Hopkins; A David Rodrigues; Manoli Vourvahis; Michael J Sorich; Andrew Rowland Journal: Front Pharmacol Date: 2019-09-27 Impact factor: 5.810
Authors: C Louwrens Braal; Elisabeth M Jongbloed; Saskia M Wilting; Ron H J Mathijssen; Stijn L W Koolen; Agnes Jager Journal: Drugs Date: 2020-12-28 Impact factor: 9.546